Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy."
Paxton says the “woke” EHR giant is intentionally making it harder for patients and families to access historical medical data, violating state law. Epic denies the allegation.
Mark Cuban's startup Cost Plus Drugs and insurer Humana are said to be working on a deal that would allow Medicare Advantage patients to buy drugs directly from manufacturers. The terms of the agreement—which Forbes reports is in its early stages—are still unknown.
The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.
A global tech and pharma supplier that introduced a generic equivalent to GE Healthcare’s Visipaque during the height of the 2022 contrast shortage has begun offering a substitute for Guerbet’s Dotarem.
An AI startup in the neuro-oncology space has received the government’s go-ahead to market software for analyzing certain fast-growing brain tumors on MRI.
The criminal saga of the X-ray business owner who got caught fleecing CMS of $2 million—while grabbing for another $1.7 million or so—has reached its epilogue.
Butterfly Network, Mindray and Philips introduced new point-of-care ultrasound offerings at ACEP 2022, the annual scientific assembly of the American College of Emergency Physicians.
GE Healthcare may ship its deep learning-based image reconstruction software called AIR Recon DL with new 3D capabilities, the company announced Sept. 29.
An experimental Alzheimer’s drug therapy has slowed cognitive and functional decline by 27% versus placebo in a double-blind, randomized study of 1,795 individuals with early signs and symptoms of the disease.
Patients with autoimmune hepatitis may be better monitored across disease stages by AI-augmented multiparametric MRI than by liver biopsy, as the imaging has proven less costly and is inherently less risky due to its noninvasiveness.